



Attorney Docket No. NATNUT-039517

RECEIVED
JAN 24 2001
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jan Wadstein *et al.*

Serial No.: 09/410,484

Group No.: 1614

Filed: 09/30/99

Examiner: H. Nguyen

Entitled: **Method Of Treating Hypertension And Reducing
Serum Lipase Activity**

**INFORMATION DISCLOSURE
STATEMENT TRANSMITTAL**

Assistant Commissioner for Patents
Washington, D.C. 20231

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Dated: January 5, 2001

By: Mary Ellen Waite

Mary Ellen Waite

Sir or Madam:

Enclosed please find an Information Disclosure Statement and Form PTO-1449, including copies of the references contained thereon, for filing in the U.S. Patent and Trademark Office.

A check for \$180.00 is also enclosed pursuant to 37 C.F.R. § 1.17(p) for filing this Information Disclosure Statement after three months as set forth in 37 C.F.R. § 1.97(c).

The Commissioner is hereby authorized to charge any additional fee or credit overpayment to our Deposit Account No. 08-1290. **An originally executed duplicate of this transmittal is enclosed for this purpose.**

Dated: January 5, 2001

J. Mitchell Jones


Registration No. 44,174

01/19/2001 REMRIS1 00000023 09410484


01 FC:125

100.00 09

MEDLEN & CARROLL, LLP
220 Montgomery Street, Suite 2200
San Francisco, California 94104
415/705-8410



Attorney Docket No. NATNET-0391



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jan Wadstein *et al.*

Serial No.: 09/410,484

Group No.: 1614

Filed: 09/30/99

Examiner:

Entitled: **Method Of Treating Hypertension And Reducing Serum Lipase Activity**

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)(1)(i)(A)	
I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.	
Dated: <u>January 5, 2001</u>	By: <u>Mary Ellen Waite</u>

Sir or Madam:

The citations listed below, copies attached, may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.

The following printed publications are referred to in the body of the specification:

- U.S. Patent No. 5,554,646
- U.S. Patent No. 5,428,072
- U.S. Patent No. 5,430,066
- U.S. Patent No. 5,585,400
- U.S. Patent Application Serial No. 09/160,416
- U.S. Patent Application Serial No. 09/270,941

- Langer, Clin. and Exper. Hypertension, 17(7):1127-44 (1995)
- Hennekens, Am. J. Medicine, 104(6A):50S-53S (1998)
- Black, JAMA, 270(6):757-59 (1993)

- Tietz *et al.*, Clin. Chem. 39(5):746-56 (1993)
- Thompson, Brit. Med. Bull. 46(4):986-1004 (1994)
- Tonstad *et al.*, Eur. J. Clin. Pharmacol. 46:405-10 (1994)
- Chin *et al.*, J. Food Comp. Anal. 5: 185-197 (1992).
- Belury, Nut. Rev. 53(4): 83-9 (1995).
- Cowan, JAOCS 72:492-99 (1950).
- Marcel and Mustafa, Lipids, 32 (10) 1019-34 (1997)

- EP patent application No. 779,033 to Unilever, N.V. describes an edible fat spread containing CLA that improves blood lipid profiles. This reference does not disclose the use of CLA to reduce blood pressure or serum lipase activity.
- EP patent application No. 839,897 to Rinoru Oil Mills Co., LTD. describes a method for producing conjugated linoleic acid by alkali isomerization of linoleic acid contained in a fat or oil. This reference does not disclose the use of CLA to reduce blood pressure or serum lipase activity.
- Scholfield and Koritalia, "A Simple Method for Preparation of Methyl trans-10,cis-12 Octadecadienoate," JOACS 47(8):303 (1970) describe the preparation of methyl t10,c12 octadecadienoate from purified methyl linoleate. This reference does not disclose the use of CLA to reduce blood pressure or serum lipase activity.
- PCT Patent Application No. WO 97/18320 to Loders describes an enzymatic method for preparing CLA compositions enriched for the t10,c12 isomer or c9,t11 isomer. This reference does not disclose the use of CLA to reduce blood pressure or serum lipase activity.
- PCT Patent Application WO 98/49129 to Henkel describes in the abstract triglycerides containing at least one conjugated linolenic acid radical. This reference does not disclose the use of CLA to reduce blood pressure or serum lipase activity.
- Sugano *et al.*, "Conjugated Linoleic Acid Modulates Tissue Levels of Chemical Mediators and Immunoglobulins in Rats," Lipids, 33(5):521-27 (1998), describe CLA produced by non-aqueous alkali isomerization which contains 18.6% trans-trans isomers. This reference does not disclose the use of CLA to reduce blood pressure or serum lipase activity.

- U.S. Pat. No. 5,856,149 to Pariza *et al.*, describes an enzymatic method for producing c9,t11 CLA. This reference does not disclose the use of CLA to reduce blood pressure or serum lipase activity.
- U.S. Pat. No. 5,855,917 to Cook *et al.*, describes a method for controlling body fat and body weight by administering conjugated 20 carbon fatty acids. This reference does not disclose the use of CLA to reduce blood pressure or serum lipase activity.
- U.S. Pat. No. 5,851,572 to Cook *et al.*, describes a method of increasing fat firmness in animals through administration of alkali isomerized CLA. This reference does not disclose the use of CLA to reduce blood pressure or serum lipase activity.
- U.S. Pat. No. 5,827,885 to Cook *et al.*, describes a method of treating animals to increase immune effector cells and enzymatically synthesized c9,t11 CLA. This reference does not disclose the use of CLA to reduce blood pressure or serum lipase activity.
- U.S. Pat. No. 5,814,663 to Cook *et al.*, describes a method of maintaining body fat in animals using non-aqueous alkali isomerized CLA. This reference does not disclose the use of CLA to reduce blood pressure or serum lipase activity.
- U.S. Pat. No. 5,804,210 to Cook *et al.*, describes a method of treating an animal with non-aqueous isomerized CLA in order to increase bone strength. This reference does not disclose the use of CLA to reduce blood pressure or serum lipase activity.
- Matreya Catalog, 1997, pp. 33-34, describes a purified preparation of c9,t11 CLA. This reference does not disclose the use of CLA to reduce blood pressure or serum lipase activity.
- Hudtwalcker & Co. AS Technical Data Sheet, exact publication date unknown, describes CLA compositions with various levels of CLA. This reference does not disclose the use of CLA to reduce blood pressure or serum lipase activity.
- Selin CLA Product Literature, 1/97, describes triglycerides incorporating CLA. This reference does not disclose the use of CLA to reduce blood pressure or serum lipase activity.
- Lipid Technology Newsletter, Peter J. Barnes, Ed., Vol. 4, No. 5, pp 85-86 (October, 1998), describes a Loders CLA product which contains approximately 80% of t10,c12


and c9,t11 isomers and minor amounts of other isomers. This reference does not disclose the use of CLA to reduce blood pressure or serum lipase activity.

- Natural Lipids Ltd. AS Technical Data Sheet, 1/20/97, describes CLA compositions with varying amounts of CLA. This reference does not disclose the use of CLA to reduce blood pressure or serum lipase activity.
- Ron Udell, Information About Conjugated Linoleic Acid, published by Soft Gel Technologies Incorporated, exact publication date unknown, describes the analysis of CLA products. This reference does not disclose the use of CLA to reduce blood pressure or serum lipase activity.
- PCT Patent Application WO 97/46230 to Wisconsin Alumni Research Foundation, describes a method for maintaining an existing level of body fat or body weight in a human through the administration of CLA. This reference does not disclose the use of CLA to reduce blood pressure or serum lipase activity.
- U.S. Patent No. 5,208,356 to Pariza, et al. describes the use of salts and esters of CLA as antioxidants and inhibitors of mold growth. A method of making the c9,t11 isomer of CLA is also described. This reference does not disclose the use of CLA to reduce blood pressure or serum lipase activity.
- European Patent Application No. 440,352 to Wisconsin Alumni Research Foundation describes a method of chelating metals in solution using CLA. This reference does not disclose the use of CLA to reduce blood pressure or serum lipase activity.
- PCT Patent Application No. WO 98/05318 to Wisconsin Alumni Research Foundation describes the use of CLA to maintain or enhance the mineral content of the bones of an animal. This reference does not disclose the use of CLA to reduce blood pressure or serum lipase activity.
- U.S. Patent No. 5,760,082 to Cook, *et al.* describes a dietetic food containing CLA. This reference does not disclose the use of CLA to reduce blood pressure or serum lipase activity.
- U.S. Patent No. 5,674,901 to Cook, *et al.* describes the use of CLA to maintain or elevate CD-4 and CD-8 levels in animals. A method for the production of CLA using bacteria isolated from a rat colon is also described. This reference does not disclose the use of CLA to reduce blood pressure or serum lipase activity.

- U.S. Patent No. 3,729,379 to Emken describes a method for producing hydroxy-conjugated fatty acids from linoleic acid soaps using dimethyl sulfoxide and soybean lipoxygenase. This reference does not disclose the use of CLA to reduce blood pressure or serum lipase activity.

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that anyone or more of these citations constitutes prior art.

Dated: January 5, 2001


J. Mitchell Jones
Registration No. 44,174

MEDLEN & CARROLL, LLP
220 Montgomery Street, Suite 2200
San Francisco, California 94104
415.705.8410